Separation of the convulsions and antidepressant-like effects produced by the delta-opioid agonist SNC80 in rats
- PMID:16163520
- PMCID: PMC1307499
- DOI: 10.1007/s00213-005-0138-9
Separation of the convulsions and antidepressant-like effects produced by the delta-opioid agonist SNC80 in rats
Abstract
Rationale: Delta-opioid agonists produce a number of behavioral effects, including convulsions, antinociception, locomotor stimulation, and antidepressant-like effects. The development of these compounds as treatments for depression is limited by their convulsive effects. Therefore, determining how to separate the convulsive and antidepressant-like characteristics of these compounds is essential for their potential clinical use.
Objective: The present study tests the hypothesis that the rate of delta-opioid agonist administration greatly contributes to the convulsive properties, but not the antidepressant-like effects, of delta-opioid agonists.
Materials and methods: The delta-opioid agonist SNC80 (1, 3.2, and 10 mg kg-1 or vehicle) was administered to Sprague-Dawley rats by intravenous infusion over different durations of time (20 s, 20, or 60 min). Convulsions were measured by observation prior to determining antidepressant-like effects in the forced swim test.
Results: Slowing the rate of SNC80 administration minimized delta agonist-induced convulsions without altering the effects of SNC80 in the forced swim test.
Conclusions: These data suggest that delta agonist-induced antidepressant properties are independent of convulsive effects, and that it may be possible to eliminate the convulsions produced by delta agonists, further promoting their potential clinical utility.
Figures





Similar articles
- Convulsant activity of a non-peptidic delta-opioid receptor agonist is not required for its antidepressant-like effects in Sprague-Dawley rats.Broom DC, Jutkiewicz EM, Folk JE, Traynor JR, Rice KC, Woods JH.Broom DC, et al.Psychopharmacology (Berl). 2002 Oct;164(1):42-8. doi: 10.1007/s00213-002-1179-y. Epub 2002 Jul 30.Psychopharmacology (Berl). 2002.PMID:12373418
- Peptidic delta opioid receptor agonists produce antidepressant-like effects in the forced swim test and regulate BDNF mRNA expression in rats.Torregrossa MM, Jutkiewicz EM, Mosberg HI, Balboni G, Watson SJ, Woods JH.Torregrossa MM, et al.Brain Res. 2006 Jan 19;1069(1):172-81. doi: 10.1016/j.brainres.2005.11.005. Epub 2005 Dec 20.Brain Res. 2006.PMID:16364263Free PMC article.
- Differential behavioral tolerance to the delta-opioid agonist SNC80 ([(+)-4-[(alphaR)-alpha-[(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-methoxyphenyl)methyl]-N,N-diethylbenzamide) in Sprague-Dawley rats.Jutkiewicz EM, Kaminsky ST, Rice KC, Traynor JR, Woods JH.Jutkiewicz EM, et al.J Pharmacol Exp Ther. 2005 Oct;315(1):414-22. doi: 10.1124/jpet.105.088831. Epub 2005 Jul 13.J Pharmacol Exp Ther. 2005.PMID:16014751Free PMC article.
- Behavioral effects of delta-opioid receptor agonists: potential antidepressants?Broom DC, Jutkiewicz EM, Rice KC, Traynor JR, Woods JH.Broom DC, et al.Jpn J Pharmacol. 2002 Sep;90(1):1-6. doi: 10.1254/jjp.90.1.Jpn J Pharmacol. 2002.PMID:12396021Review.
- The antidepressant -like effects of delta-opioid receptor agonists.Jutkiewicz EM.Jutkiewicz EM.Mol Interv. 2006 Jun;6(3):162-9. doi: 10.1124/mi.6.3.7.Mol Interv. 2006.PMID:16809477Review.
Cited by
- β-Arrestin 2 dependence of δ opioid receptor agonists is correlated with alcohol intake.Chiang T, Sansuk K, van Rijn RM.Chiang T, et al.Br J Pharmacol. 2016 Jan;173(2):332-43. doi: 10.1111/bph.13374.Br J Pharmacol. 2016.PMID:26507558Free PMC article.
- Delta-opioid receptor-mediated modulation of excitability of individual hippocampal neurons: mechanisms involved.Moravcikova L, Moravcik R, Jezova D, Lacinova L, Dremencov E.Moravcikova L, et al.Pharmacol Rep. 2021 Feb;73(1):85-101. doi: 10.1007/s43440-020-00183-2. Epub 2020 Nov 8.Pharmacol Rep. 2021.PMID:33161533
- Agonist-induced phosphorylation bar code and differential post-activation signaling of the delta opioid receptor revealed by phosphosite-specific antibodies.Mann A, Liebetrau S, Klima M, Dasgupta P, Massotte D, Schulz S.Mann A, et al.Sci Rep. 2020 May 22;10(1):8585. doi: 10.1038/s41598-020-65589-7.Sci Rep. 2020.PMID:32444688Free PMC article.
- Discovery, synthesis, and molecular pharmacology of selective positive allosteric modulators of the δ-opioid receptor.Burford NT, Livingston KE, Canals M, Ryan MR, Budenholzer LM, Han Y, Shang Y, Herbst JJ, O'Connell J, Banks M, Zhang L, Filizola M, Bassoni DL, Wehrman TS, Christopoulos A, Traynor JR, Gerritz SW, Alt A.Burford NT, et al.J Med Chem. 2015 May 28;58(10):4220-9. doi: 10.1021/acs.jmedchem.5b00007. Epub 2015 May 7.J Med Chem. 2015.PMID:25901762Free PMC article.
- Targeting opioid dysregulation in depression for the development of novel therapeutics.Browne CA, Lucki I.Browne CA, et al.Pharmacol Ther. 2019 Sep;201:51-76. doi: 10.1016/j.pharmthera.2019.04.009. Epub 2019 Apr 30.Pharmacol Ther. 2019.PMID:31051197Free PMC article.Review.
References
- Abreu ME, Bigelow GE, Fleisher L, Walsh SL. Effects of intravenous injection speed on responses to cocaine and hydromorphone in humans. Psychopharmacology (Berl) 2001;154:76–84. - PubMed
- Baamonde A, Daugé V, Ruiz-Gayo M, Fulga IG, Turcaud S, Fournié-Zaluski MC, Roques BP. Antidepressant-type effects of endogenous enkephalins protected by systemic RB 101 are mediated by opioid δ and dopamine D1 receptor stimulation. Eur J Pharmacol. 1992;216:157–166. - PubMed
- Baird TJ, Deng S-X, Landry DW, Winger G, Woods JH. Natural and artificial enzymes against cocaine. I. Monoclonal antibody 15A10 and the reinforcing effects of cocaine in rats. J Pharmacol Exp Ther. 2000;295:1127–1134. - PubMed
- Broom DC, Jutkiewicz EM, Folk JE, Traynor JR, Rice KC, Woods JH. Nonpeptidic delta-opioid receptor agonists reduce immobility in the forced swim assay in rats. Neuropsychopharmacology. 2002a;26(6):744–755. - PubMed
- Broom DC, Jutkiewicz EM, Folk JE, Traynor JR, Rice KC, Woods JH. Convulsant activity of a nonpeptidic delta-opioid receptor agonist is not required for antidepressant-like effects. Psychopharmacology (Berl) 2002b;164(1):42–48. - PubMed
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical